Latest Breakthrough nod goes to Novartis

Share this article:

The FDA announced Tuesday that it has approved the Novartis lung cancer drug Zykadia, or ceritinib (previously known as LDK378).

The approval is for patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC), specifically those who were previously treated with Pfizer's Xalkori (crizotinib). Xalkori is the only other approved ALK tyrosine kinase inhibitor but one which (like many molecular targeted drugs) encounters resistance.

The approval is the fourth drug with the FDA's Breakthrough Therapy designation to be approved by the agency.

The drug is also considered an orphan product and is notable for its approval speed: the approval deadline was August 24, four months from now.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters